arrow
D

Daniel H. Wiseman

University of Manchester
H指数:23
被引数:2,559

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee

定义异基因造血细胞移植后骨髓增生异常/骨髓增生性肿瘤的缓解和复发,并优化移植结果:EBMT实践协调与指南委员会的建议

2026-04-010
PRE
INCORPORATING TET2 VARIANT ALLELE FREQUENCY ENHANCES PROGNOSTICATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA: A MULTICENTER STUDY

纳入TET2变异等位基因频率可增强慢性粒单细胞白血病的预后评估:一项多中心研究

2025-09-010
PRE
Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis

端粒损耗成为衰老造血和白血病发生过程中克隆选择的一种机制。

2025-08-280
OAAI
Synergistic effect of concurrent high molecular risk mutations and lower JAK2 mutant variant allele frequencies on prognosis in patients with myelofibrosis-insights from a multicenter study
LEUKEMIA
IF13.4
2024-10-040
PRE
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts
2024-07-260
OAAI
Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium
2024-05-151
OAAI
Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths
2023-09-0118
OAAI
Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils
2023-06-0119
OAAI
Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in SF3B1-mutated myelodysplasia
2023-03-0110
OAAI
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes

Abnl-marro 001研究: MDS/MPN重叠综合征中随机分配的活性髓系靶化合物组合的1-2期研究

2022-09-248
OAAI